The Phase 1 clinical trial, STRIKE-001 (NCT07103018), is a multi-center, open-label dose escalation of KTX-2001 monotherapy (Part A) and in combination with darolutamide, an oral, nonsteroidal ...

Targeted therapies, bispecifics, and CAR T-cell therapies are giving patients with multiple myeloma hope for long-term remission or a potential cure.

Bristol Myers Squibb stock rose moderately Thursday on better-than-expected fourth-quarter metrics and a strong 2026 outlook.

The investigational oral therapy KTX-1001, also known as gintemetostat, is catching interest as a potential treatment for a subgroup of patients with multiple myeloma, as an expert explained in a ...

Farooq Oreagba, popularly known as “Mr Steeze,” has opened up about his battle with cancer on World Cancer Day on February 4 2026.

Francisco Barahona is recovering at home with a shattered arm after Surrey Memorial Hospital, he says, refused to treat him ...

Nocturnal symptoms and musculoskeletal pain are filtered through relapse fear, driving repetitive interpretation of ...

Nonresponse to bridging therapy and high lymphocyte count were predictive of parkinsonism and nonrelapse mortality (NRM) after treatment with ciltacabtagene autoleucel (cilta-cel; Carvykti) in ...

According to him, the results arrived a week later with words he says he will never forget.“The crucial sentence was that the images indicated a high possibility of malignant activity. In a nutshell, ...

The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for the treatment of ...

(Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results from a prior Phase 2 clinical study evaluating ...

Bristol-Myers Squibb (BMY) stock gains after the company beat with its Q4 2025 financials and 2026 outlook as its growth portfolio outperforms. Read more here.